Published in Proc Natl Acad Sci U S A on November 23, 2015
Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments. Immunotargets Ther (2016) 0.76
A critical role for IRF5 in regulating allergic airway inflammation. Mucosal Immunol (2016) 0.75
Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight (2017) 0.75
Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis. J Invest Dermatol (2016) 0.75
IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol (2006) 7.98
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature (2005) 5.37
Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med (1997) 4.06
Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol (2012) 2.72
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol (2013) 2.22
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum (2009) 1.88
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med (2014) 1.72
Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum (2003) 1.37
Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol (2010) 1.37
Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum (2001) 1.36
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol (2004) 1.20
Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum (2009) 1.19
Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci U S A (2012) 1.15
Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol (2012) 1.11
Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol (2010) 1.07
Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J Rheumatol (2010) 1.01
Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol (2008) 1.00
High-mobility group box-1 and its role in angiogenesis. J Leukoc Biol (2014) 0.99
IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis (2012) 0.98
The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol (2014) 0.97
Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol (2013) 0.95
Vasculopathy in scleroderma. Semin Immunopathol (2015) 0.90
Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun (2014) 0.88
Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheumatol (2015) 0.85
Toll-like receptor 4 in inflammation and angiogenesis: a double-edged sword. Front Immunol (2014) 0.85
Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheumatol (2015) 0.83
Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology (2013) 0.81
Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol (2008) 0.81
Association between IRF5 polymorphisms and autoimmune diseases: a meta-analysis. Genet Mol Res (2014) 0.78
Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology (Oxford) (2005) 0.77